🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Pharmas aid FTSE, offsetting weak miners

Published 05/03/2011, 12:40 PM
Updated 05/03/2011, 12:44 PM
UK100
-
C
-
AA
-
BARC
-
AZN
-
RIO
-
EMG
-
ITV
-
BMAm
-

* FTSE 100 up 0.2 percent

* Drugmakers lifted by U.S. deal activity

* Smiths top faller on Detection unit problems

By Tricia Wright

LONDON, May 3 (Reuters) - Drugmakers helped Britain's top share index rise modestly on Tuesday, buoyed by deal activity in the United States, as traders mooted the possibility that a recent equity rally may falter.

Miners hampered the FTSE 100's progress though, hurt by easing metals prices on renewed fears about demand, with Rio Tinto off 1.6 percent on talk that the miner was lining up a bid to buy U.S. aluminium producer Alcoa.

Neither Rio Tinto nor Alcoa would comment on the rumours.

The UK blue-chip index ended 12.98 points, or 0.2 percent, firmer at 6,082.88. The index has risen nearly 3.8 percent since its April lows.

"The recent rally appears to be running out of steam around this year's highs at 6,105," Michael Hewson, market analyst at CMC Markets, said.

"Until such time as we see a close above this resistance area, the FTSE will remain susceptible to pull backs towards the 5,800 area," he said.

Drugmakers were boosted after Israel-based Teva Pharmaceuticalss unveiled a $6.8 billion deal on Monday to buy U.S. Cephalon.

AstraZeneca was among the top FTSE 100 risers, up 2.4 percent, recovering its poise after a 3.5-percent drop on Thursday when it reported first-quarter results, with Citigroup saying the numbers are "not as bad as (the) market implies".

BUYING OPPORTUNITY

Observers said that investor confidence, recently aided by solid corporate earnings from both sides of the Atlantic, may be sapped by macroeconomic fears in the near term, although any weakness could be seized upon as a buying opportunity.

"A number of macro factors could trigger investors to try and book profits; oil price, concern about inflation, worries about overheating in emerging markets, the U.S. debt position," Henk Potts, market strategist at Barclays Wealth, said.

"(However), long term, the outlook remains very strong (and) equity markets remain our preferred asset class," he added, seeing the best prospects in cyclical stocks, with industrials and technology his top picks.

Weakness was seen on the high street, as data from the Confederation of British Industry highlighted the grim outlook facing retailers. Next, scheduled to issue a trading update on Wednesday, fell 0.7 percent, while Marks & Spencer dipped 0.9 percent.

ITV which relies on advertising from the retailers, fell 2.2 percent.

Smiths was the biggest laggard, off 5.7 percent, after the technology firm said the head of its Detection unit would step down immediately, as trading at the airport security business fell short of the board's expectations.

Man Group, meanwhile, topped the blue-chip leader board, up 3.3 percent, as the hedge fund unveiled a $1.5 billion fund in Japan, its biggest product launch since the financial crisis. (Additional reporting by David Brett; Editing by Elaine Hardcastle)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.